Hercules, CA — September 12, 2012 — Bio-Rad Laboratories, Inc. today announced the launch of its Mini-PROTEAN TGX (Tris-glycine extended) Stain-Free precast gels in gradient formats 4–15% and 4–20%. Ideal for samples that contain a broad range of protein sizes, the new formats extend Bio-Rad’s line of mini- and midi-sized stain-free precast gels, providing researchers with the fastest separation and in-gel protein visualization capabilities available for Laemmli-based PAGE.
Typical polyacrylamide gel staining methods that follow Coomassie protocols can take four or more hours to complete. The Mini-PROTEAN TGX Stain-Free precast gels include a unique trihalo compound that allows rapid fluorescent detection of proteins in gels or on membranes without the need for staining. When researchers use the Mini-PROTEAN TGX Stain-Free precast gels as part of Bio-Rad’s V3 Western Workflow™, they can achieve complete protein separation, gel imaging, and data analysis in 20 minutes.
Other key benefits of Mini-PROTEAN TGX Stain-Free precast gels in gradient format include:
- Greater transfer efficiency — proteins can be transferred onto PVDF or nitrocellulose membranes in as little as 3 minutes with the Trans-Blot® Turbo™ system
- Versatility — the same gel can be used for western blotting, standard staining methods, and mass spectrometry analysis of proteins
- Cost-effectiveness — unlike other precast gels that require specialized buffer systems and stains, the Mini-PROTEAN TGX Stain-Free precast gels use inexpensive standard Laemmli buffer and do not require staining and destaining, keeping running costs low
The Mini-PROTEAN TGX Stain-Free precast gels are available in a wide range of percentages: 7.5%, 10%, 12%, 4–15%, 4–20%, and Any kD™ (offers optimal resolution in the 10–100 kD range). Gels can be stored for up to 12 months without loss of performance.
For product details or to order Mini-PROTEAN TGX Stain-Free gels, visit http://bit.ly/MP_SFTGX.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company’s risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Marie Nguyen
Bio-Rad Laboratories, Inc.
510-741-5312
Marie_Nguyen@bio-rad.com
Ken Li
Chempetitive Group
312-997-2436 x 112
kli@chempetitive.com